News

2012 Annual General Meeting Address to Shareholders by Chairman and CEO 24 October, 2012 ADDRESS BY CHAIRMAN ? MR. DAVID WILLIAMS Last year I reported that our changed approach to the business allowed us to achieve a NPAT of $1.74 million for FY11. This year we recorded a record NPAT of $2.72 million. All shareholders […]

CONTINUING GROWTH AND RECORD PROFIT Medical Developments International Limited. (?MDI?) (ASX:MVP) delivered a Record Net Profit After Tax of $2,704,024 for the year ended 30 June 2012, which represents a 55% increase on FY2011 ($1,743,270).? MDI finished the year with $3.5 million of cash reserves after paying $2.7 million on clinical trials and two 3 […]

CONTINUING GROWTH AND RECORD PROFIT Medical Developments International Limited. (“MDI”) (ASX:MVP) delivered a Record Net Profit After Tax of $2,704,024 for the year ended 30 June 2012, which represents a 55% increase on FY2011 ($1,743,270).  MDI finished the year with $3.5 million of cash reserves after paying $2.7 million on clinical trials and two 3 […]

Medical Developments International Limited (ASX: MVP) is delighted to confirm the 300th and final patient has been enrolled into its European Phase III trial. The trial commenced in August of 2011 and has successfully completed on time and on budget. The Phase III trial is a randomized, double blind, multi-centre, placebo controlled study to evaluate […]

The Board of Directors of Medical Developments International Ltd. (ASX:MVP) announced a profit guidance upgrade on 22 June, 2012 . On the 24th April 2012 the company announced profit guidance of circa $2.2M for FY12; up from FY11 $1.74M. The latest upgrade is that Net Profit after Tax is expected to be 10% greater than […]

Medical Developments is pleased to announce it has established a UK subsidiary company and appointed a European Business Development Manager based in London. Initially our European Business Development Manager will capitalize on the sale of MVP?s range of Medical Device?s and in particular our leading range of Asthma Devices.? This follows the recent successful signing […]

Further Earnings Guidance The Board of Directors of Medical Developments International Ltd. (ASX:MVP) advise the market that further to the excellent result announced for H1 FY12, the company has continued to deliver strong earnings growth in H2 FY12. The Directors of MVP now advise Net Profit after Tax for FY12 is expected to be least […]

Medical Developments is delighted to confirm the following results from its Interim Dividend declared on 23 February, 2012. 64% of shareholders chose to reinvest in shares in the company rather than take a cash dividend.? The remaining shareholders were paid the Internim Dividend of 3 cents on 11 April, 2012. The CEO Mr John Sharman […]